Steven Henriksen, PhD
Vice President for Research & Biotechnology
Professor of Pharmacology in COMP
Graduate College of Biomedical Sciences
Join year: 2005
University of California , Santa Barbara B.A. 1966 Analytical Biology
Stanford University School of Medicine Ph.D. 1973 Neuroscience
Stanford University Dept. of Psychiatry Postdoctoral 1973-74 Neuroscience
NIMH St. Elizabeth 's Hospital, Washington, D.C. Postdoctoral 1974-76 Neuropharmacology
He came to Western University in 2005 from the Scripps Research Insitute in La Jolla, California, where he led a multidisciplinary team of scientists investigating feline viruses, the mechanisms of mammalian sleep and drug abuse neurocircuitry.
Dr. Henriksen's laboratory studies the functional organization of neural circuits where intrinsic capacities for both normal and abnormal brain functions reside. To understand how the brain initiates, promotes, and alters behavior, our goal is to understand the hierarchy that neuronal circuits and their chemical messengers have in producing appropriate responses to external and internal sensory events. This approach requires in vivo studies and is best described as a "systems" analysis of behavior. His colleagues and he employ anatomical, neuropharmacological, electrophysiological, molecular and behavioral tools to reveal the hierarchies of the cellular components of brain circuits underling behavioral integration and functional pathology. They study animals whose central nervous system is either intact but one that can be compromised by either viral infection, genetic manipulations or by molecular engineering.
American Board of Sleep Medicine Diplomat 1985 Sleep Research
•Madden, L., Zandonatti, M., Flynn, C., Taffe, M., Marcondes, M., Schmitz, J., Reimann, K., Henriksen, S., Fox, H. CD8+ cell depletion amplifies the acute retroviral syndrome. J. NeuroVirol., 10(suppl. 1): 1-9, 2004.
•Laviolette, S., Gallegos, R., Henriksen, S., van der Kooy, D. Opiate state controls bi-directional reward signaling via GABAA receptors in the ventral tegmental area. Nature Neurosci., 7(2): 160-9, 2004.
•Cloak, C., Chang, L., Ernst, T., Barr, M., Huitr, S., Sanchez-Alavez, M., Phillips, T., Henriksen, S. Methamphetamine & AIDS: 1HMRS in a feline model of human disease. J. Neuroimm., 147: 16-20, 2004.
•Xu, Y., Reinscheid, R., Huitron, S., et al. Brucher, F., Zeng, J., Ly, N., Henriksen, S., de Lecea, L., Civelli, O. Neuropeptide S: A neuropeptide promoting arousal and anxiolytic-like effects. Neuron, 43:487-97, 2004.
•Huitron, S., Sanchez, M., Wills, D., Cravatt, B., Henriksen, S. Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase. SLEEP, 27(5): 857-65, 2004.
•Huitron, S., de Rozieres, S., et. al., Fox, H., Torbett, B., Henriksen, S., Elder, J. Resolution & prevention of FIV-induced neurological deficits by treatment w/ protease inhibitor, TL-3. J. Virol., 78(9):4525-32, 2004.
•S anchez, M., Gombart, L., et. al., Henriksen, S., Criado, J. Physiological, behavioral effects of METH administration in mouse model of endotoxemia: prelim study. Pharm., Biochem., Behav., 77:365-70, 2004.
•de Rozieres, S., Swan, C., Sheeter, D., et. al., Huitron, S., Henriksen, S., Torbett, B., Elder, J. Assessment of FIV-C infection of cats as a function of treatment with protease inhibitor, TL-3. Retrovirol., 1(1):38, 2004.
•Criado, J., S anchez, M., et al., Henriksen, S., Race, R., Manson, J., Chesebro, B., Oldstone, M.B. Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neuron. Neurobiol. Dis., 19(1-2):255-65, 2005.
•Madden, L., Flynn, C., Zandonatti, M., May, M., Parsons, L., Katner, S., Henriksen, S., Fox, H. Modeling human METH exposure in non-human primates: Chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities. Neuropsychopharm. 30: 350-9, 2005